Cetuximab targeted therapy: A new treatment paradigm for advanced colorectal cancer

Clinical Colorectal Cancer

Volumn 3, Issue 4, 2004, Pages 205-

  Chu, Edward ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CHEMOSENSITIVITY; CLINICAL OBSERVATION; CLINICAL TRIAL; COLON CARCINOGENESIS; COLORECTAL CANCER; DNA REPAIR; DRUG APPROVAL; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; HUMAN; MONOTHERAPY; OUTCOMES RESEARCH; SIGNAL TRANSDUCTION; TREATMENT PLANNING; VALIDATION PROCESS;

EID: 1842451995     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2004.n.001     Document Type: Editorial

References (4)

1. Food and Drug Administration. FDA Approves Erbitux for Colorectal Cancer. Rockville, MD: Dept of Health and Human Services; February 12, 2004. P04-P20.
2. Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003; 25:252 (Abstract #1012).
3. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refratory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20:3A (Abstract #7).
4. Saltz L, Meropol NJ, Loehrer PJ, et al. Single agent IMC-C225 (Erbitux™) has activity in CPT-11-refratory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002; 21:127a (Abstract #504).